Travere Therapeutics

ISIN US89422G1076

 | 

WKN A2QHYP

Market cap (in EUR)
5,309 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
Toon meer Toon minder
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financiële kerngegevens

Kerncijfers

Marktkapitalisatie, EUR 5,309 m
WPA, EUR -0.65
KBV 250.5
K/W -
Dividendrendement 0.00%

Income statement (2025)

Omzet, EUR 435 m
Netto-inkomen, EUR -45 m
Winstmarge -10.24%

What ETF is Travere Therapeutics in?

There are 4 ETFs which contain Travere Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Travere Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weging Investeringsfocus Fondsgrootte (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.38%
Equity
United States
Health Care
Biotech
 69
Vanguard Russell 2000 U.S. Small-Cap UCITS ETF USD Dist 0.16%
Equity
United States
Small Cap
 3
WisdomTree Russell 2000 0.16%
Equity
United States
Small Cap
 7
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.07%
Equity
United States
Small Cap
 226
Nieuwste artikelen
Populaire artikelen
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.

Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.